Immunomodulatory Role of an Ayurvedic Formulation on Imbalanced Immunometabolics during Inflammatory Responses of Obesity and Prediabetic Disease
Figure 5
Body weights, fasting blood glucose, and insulin levels in high-fat high-sugar fed control were lower than normal diet fed control mice and Kal-1 treatment restored the body weights and blood glucose levels successfully. After obesity and diabetes induction period up to 21 weeks, Kal-1 treatment was started from week 22 to 30. (a)(A) Effect of Kal-1 treatment on body weights in high-fat high-sugar diet fed mice at weeks 22, 26, and 30. Treatment with all doses (5, 20, and 75 μL) of Kal-1 was started only after 21 weeks (induction period) along with high-fat high-sugar diet. (B) Effect of Kal-1 treatment with optimum dose (75 μL) on body weights in high-fat high-sugar diet fed mice only at week 30. (b)(A) Effect of Kal-1 treatment on fasting blood glucose levels in high-fat high-sugar diet fed mice at weeks 22, 26, and 30. Treatment with all doses (5, 20, and 75 μL) of Kal-1 was started only after 21 weeks (induction period) along with high-fat high-sugar diet. (B) Effect of Kal-1 treatment with optimum dose (75 μL) on fasting blood glucose in high-fat high-sugar diet fed mice only at week 30. (c) Effect of Kal-1 treatment on fasting insulin levels in high-fat high-sugar diet fed mice at week 30. Treatment with all doses (5, 20, and 75 μL) of Kal-1 was started only after 21 weeks (induction period) along with high-fat high-sugar diet. LF: low-fat control, HF: high-fat high-sugar control. All the values represent mean ± SEM from five animals.
